CCL5, CXCL10 and CXCL11 Chemokines in Patients with Active and Stable Relapsing-Remitting Multiple Sclerosis

Publisher： Karger

E-ISSN： 1423-0216|18|1|67-72

ISSN： 1021-7401

Source： Neuroimmunomodulation, Vol.18, Iss.1, 2010-08, pp. : 67-72

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

TRAF2 is Upregulated in Relapsing-Remitting Multiple Sclerosis

By  

Neuroimmunomodulation, Vol. 20, Iss. 3, 2013-04 ,pp. : 177-183

Karger

Access to resources Recommend Favorite

Interleukin-17A Levels Vary in Relapsing-Remitting Multiple Sclerosis Patients in Association with Their Age, Treatment and the Time of Evolution of the Disease

By  

Neuroimmunomodulation, Vol. 23, Iss. 1, 2015-11 ,pp. : 8-17

Karger

Access to resources Recommend Favorite

Severe Disability in Patients with Relapsing-Remitting Multiple Sclerosis Is Associated with Profound Changes in the Regulation of Leptin Secretion

By  

Neuroimmunomodulation, Vol. 20, Iss. 6, 2013-08 ,pp. : 341-347

Karger

Access to resources Recommend Favorite

Quantitative MRI and Cerebrospinal Fluid Inflammatory Mediators in Brazilian Patients with Relapsing-Remitting Multiple Sclerosis before and after Treatment with Immunomodulators: A Longitudinal Study

By  

Neuroimmunomodulation, Vol. 19, Iss. 5, 2012-03 ,pp. : 277-282

Karger

Access to resources Recommend Favorite

FADD Is Upregulated in Relapsing Remitting Multiple Sclerosis

By  

Neuroimmunomodulation, Vol. 21, Iss. 5, 2014-03 ,pp. : 221-225

Karger

Access to resources Recommend Favorite